[Sensitivity of esophageal cancer to anticancer agents and supplementary chemotherapy combined with surgical treatment].
The authors examined the sensitivities of esophageal cancer to Bleomycin (BLM), Peplomycin (PEP), Cisplatin (CDDP) and 5-FU by the INAS method using 3H-thymidine or 14C-formate as labeled precursors, and determined the concentrations of anticancer agents in cancer lesions by the Band Culture method. On the other hand, the authors investigated the superiority or inferiority of various methods of BLM administration by observing the prevention effect of BLM on the development of experimental esophageal cancer in rats. Forty-three cases out of 76, 57%, showed a sensitivity to BLM, 60% to PEP, 38% to CDDP and 56% to 5-FU. As to the types of roentgenological findings, the superficial and tumorous types showed a high sensitivity rate. As to the types of macroscopical findings, the protruded and superficial types showed a high sensitivity rate. As to the types of histological findings, well differentiated squamous cell carcinoma showed a high sensitivity rate. Sensitivity was higher in metastatic lymph nodes than in main cancer lesions. Tumor tissues which had undergone previous hyperthermic management (at 42 degrees C) showed a higher sensitivity than those which had not. PEP at a half dose brought about the same grade of anticancer effect as BLM. The sensitivities of esophageal cancer to various anticancer agents showed individual differences among clinical cases. Therefore, combination chemotherapy for esophageal cancer was thought to be an effective administration method. The divided administration of small doses of BLM was thought to be more superior than the one-shot administration of a large dose for esophageal cancer. The results of the INAS sensitivity test were perfectly coincident with the effects of chemotherapy in clinical cases of esophageal cancer.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology; D002250:Carbon Radioisotopes; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004938:Esophageal Neoplasms / Q000628:therapy*; D006801:Humans; D008207:Lymphatic Metastasis / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D014316:Tritium
D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D014316:Tritium; D001761:Bleomycin